BUY SALESFORCE: Redburn analyst Neil Steer initiated coverage of Salesforce ($CRM) with a Buy rating and $320 fair value estimate. The company has "incredible" revenue and earnings predictability along with "stellar" cash generation, Steer told investors in a research note. The analyst believes Salesforce will "will continue to prosper" and remain dominant in the customer experience management solutions category. While the near-term valuation multiples could look expensive, Salesforce's longer-term cash flow metrics highlight the stock's attractiveness, Steer added. OPPORTUNITY REFLECT IN VALUATION: Wedbush analyst Ygal Arounian initiated coverage of Squarespace ($SQSP) with a Neutral rating and $70 price target. The analyst sees a large market opportunity and core growth rates that are appropriately reflected in current valuation after a surge in shares since listing. Arounian believes the performance appropriately reflects the strong industry tailwinds that should support Squarespace's business, as well as the relatively strong position Squarespace is in within the portion of the market it most often plays in, which is Do-It-Yourself web building for SMBs. Barclays analyst Trevor Young also initiated coverage of Squarespace with an Equal Weight rating and $70 price target. Web tools is a highly competitive category and Squarespace is subscale versus peers and growing more slowly, Young told investors in a research note. The analyst believes Squarespace will likely win market share but that it will see margin pressure as it invests to expand its tech capabilities. TO THE SIDELINES AFTER SURVEY: JPMorgan analyst Tessa Romero downgraded Global Blood Therapeutics ($GBT) to Neutral from Overweight with a price target of $36, down from $70, after conducting a survey of 25 physicians in conjunction to assess the current and future treatment landscape for sickle cell disease. The analyst sees a "meaningful" long-term market opportunity for Oxbryta but says the feedback was "more mixed" on the overall profile/clinical experience with the drug. This could translate into more gradual growth over time, Romero told investors in a research note. Based on the survey work, the analyst believes estimates in 2022 and beyond "may still need to adjust further downward." As such, Romero sees a fairly balanced risk/reward for the stock at current levels. REVENUE GROWTH: Morgan Stanley analyst Jorge Kuri initiated coverage of dLocal ($DLO) with an Overweight rating and $72 price target. The shift from cash to plastic and from offline to online commerce has "plenty of runway" in emerging markets, leading him to estimate revenue growth of 123% in 2021, 87% in 2022, and 67% in 2023 for a "solid" three-year compound annual growth rate of 91% for dLocal. While shares are up 128% since the IPO, Kuri thinks the company's growth opportunity is "still not fully priced in." More cautious, Citi analyst Ashwin Shirvaikar initiated coverage of dLocal with a Neutral rating and $50 price target. While Shirvaikar sees a large opportunity for dLocal, which enables emerging market commerce and payments, he is held back from a higher rating by the stock's valuation and risks that include a limited operating history, lockup considerations, internal control factors, the fact it is a controlled corporation, and client concentration. Goldman Sachs analyst Tito Labarta also started coverage of dLocal with a Neutral rating and $30 price target. dLocal is a unique company in Latin America payments that exhibits "differentiated characteristics of sustainable high returns and growth," Labarta told investors in a research note. However, the analyst thinks the stock price is already discounting strong growth in the medium term. LIMITED DOWNSIDE: BTIG analyst Carl Reichardt upgraded Toll Brothers ($TOL) to Neutral from Sell without a price target. While the analyst remains concerned about some of Toll's current pricing practices and broader strategies, at its current valuation, he feels downside from here is more limited. Reichardt no longer believes the shares will underperform peers nor the market in the intermediate term, though remains worried about the company's lack of local market scale and aggressive "best offer" pricing strategy in some communities.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .